









市場行情
/
股票
/
nasdaq-omer
/

Omeros Corp

OMER

15.360USD

+6.610+75.54%

收盤 12/24, 13:00（美東）報價延遲15分鐘

1.08B總市值

虧損本益比TTM



Omeros Corp

15.360

+6.610+75.54%

概覽公司財務分析

概覽

公司

財務

分析

關於 Omeros Corp 公司

Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.

Omeros Corp簡介



公司代碼OMER

公司名稱Omeros Corp

上市日期Oct 08, 2009

CEODemopulos (Gregory A)

員工數量202

證券類型Ordinary Share

年結日Oct 08

公司地址201 Elliott Avenue West

城市SEATTLE

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編98119

電話12066765000

網址https://www.omeros.com/

公司代碼OMER

上市日期Oct 08, 2009

CEODemopulos (Gregory A)

Omeros Corp公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Peter A. Demopulos, M.D.

Director

372.90K

Dr. Leroy E. Hood, M.D., Ph.D.

Independent Director

74.39K

Mr. Thomas J. Cable

Lead Independent Director

35.07K

Mr. Arnold C. Hanish, CPA

Independent Director

12.40K

Dr. Mariana N. Dimitrova, Ph.D.

Vice President - Chemistry, Manufacturing and Controls

Mr. Peter B. Cancelmo, J.D.

Vice President, General Counsel, Secretary

Dr. Thomas F. Bumol, Ph.D.

Independent Director

Dr. Catherine A. Melfi, Ph.D.

Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer

DR. Gregory A. Demopulos, M.D.

Chairman of the Board, President, Chief Executive Officer

Mr. David J. Borges

Chief Accounting Officer, Vice President - Finance, Treasurer

名稱

名稱/職務

職務

持股

持股變動

Dr. Peter A. Demopulos, M.D.

Director

372.90K

Dr. Leroy E. Hood, M.D., Ph.D.

Independent Director

74.39K

Mr. Thomas J. Cable

Lead Independent Director

35.07K

Mr. Arnold C. Hanish, CPA

Independent Director

12.40K

Dr. Mariana N. Dimitrova, Ph.D.

Vice President - Chemistry, Manufacturing and Controls

Mr. Peter B. Cancelmo, J.D.

Vice President, General Counsel, Secretary

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 12月5日週五

持股股東

股東類型

持股股東

佔比

Ingalls & Snyder LLC (Asset Management)

5.79%

BlackRock Institutional Trust Company, N.A.

5.78%

The Vanguard Group, Inc.

4.72%

Stifel, Nicolaus & Company, Incorporated

2.56%

Morgan Stanley & Co. LLC

2.25%

其他

78.91%

持股股東

佔比

Ingalls & Snyder LLC (Asset Management)

5.79%

BlackRock Institutional Trust Company, N.A.

5.78%

The Vanguard Group, Inc.

4.72%

Stifel, Nicolaus & Company, Incorporated

2.56%

Morgan Stanley & Co. LLC

2.25%

其他

78.91%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

16.88%

Investment Advisor

15.84%

Hedge Fund

7.54%

Research Firm

5.37%

Individual Investor

2.79%

Bank and Trust

0.86%

Insurance Company

0.10%

Pension Fund

0.07%

其他

50.55%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

243

29.83M

43.83%

+1.23M

2025Q2

255

30.16M

44.94%

-422.08K

2025Q1

263

30.38M

51.89%

-522.27K

2024Q4

256

29.32M

50.59%

-441.66K

2024Q3

242

27.89M

48.13%

-1.92M

2024Q2

248

27.65M

47.72%

-3.10M

2024Q1

269

28.11M

48.16%

-3.03M

2023Q4

275

27.52M

43.79%

-6.21M

2023Q3

299

30.25M

48.14%

-4.77M

2023Q2

303

29.52M

46.99%

+306.67K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Ingalls & Snyder LLC (Asset Management)

3.98M

5.85%

+5.10K

+0.13%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.69M

5.43%

-328.94K

-8.18%

Jun 30, 2025

The Vanguard Group, Inc.

3.28M

4.82%

+46.32K

+1.43%

Jun 30, 2025

Stifel, Nicolaus & Company, Incorporated

1.52M

2.24%

-33.76K

-2.17%

Jun 30, 2025

Morgan Stanley & Co. LLC

1.09M

1.6%

+501.25K

+85.73%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.37M

2.01%

+739.00

+0.05%

Jun 30, 2025

Two Sigma Investments, LP

1.09M

1.61%

+971.88K

+802.28%

Jun 30, 2025

Demopulos (Gregory A. M.D.)

2.03M

2.98%

May 23, 2025

State Street Investment Management (US)

1.20M

1.76%

-156.01K

-11.50%

Jun 30, 2025

持股ETF



更新時間: 12月2日週二

機構名稱

佔比

Invesco NASDAQ Future Gen 200 ETF

0.94%

iShares Micro-Cap ETF

0.09%

Invesco Nasdaq Biotechnology ETF

0.05%

ProShares Ultra Nasdaq Biotechnology

0.05%

ProShares UltraPro Russell2000

0.02%

Invesco RAFI US 1500 Small-Mid ETF

0.02%

Proshares Ultra Russell 2000

0.02%

ProShares Hedge Replication ETF

0.02%

iShares Russell 2000 Growth ETF

0.02%

Global X Russell 2000 ETF

0.02%

Invesco NASDAQ Future Gen 200 ETF

佔比0.94%

iShares Micro-Cap ETF

佔比0.09%

Invesco Nasdaq Biotechnology ETF

佔比0.05%

ProShares Ultra Nasdaq Biotechnology

佔比0.05%

ProShares UltraPro Russell2000

佔比0.02%

Invesco RAFI US 1500 Small-Mid ETF

佔比0.02%

Proshares Ultra Russell 2000

佔比0.02%

ProShares Hedge Replication ETF

佔比0.02%

iShares Russell 2000 Growth ETF

佔比0.02%

Global X Russell 2000 ETF

佔比0.02%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Omeros Corp的前五大股東是誰？



Omeros Corp的前五大股東如下：
Ingalls & Snyder LLC (Asset Management)
持有股份：3.98M
佔總股份比例：5.85%。
BlackRock Institutional Trust Company, N.A.
持有股份：3.69M
佔總股份比例：5.43%。
The Vanguard Group, Inc.
持有股份：3.28M
佔總股份比例：4.82%。
Stifel, Nicolaus & Company, Incorporated
持有股份：1.52M
佔總股份比例：2.24%。
Morgan Stanley & Co. LLC
持有股份：1.09M
佔總股份比例：1.60%。